Brilinta approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most common type of heart disease.
Läs mer